Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib plus fulvestrant or letrozole after CDK4/6 inhibitor progression in PIK3CA-mutant HR-positive/HER2-negative advanced breast cancer
2016-004586-67Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alpelisib in breast cancer (2 cohorts), sponsored by Novartis. Primary endpoint: 6-month progression-free rate. Started Apr 2017; status: completed.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-004586-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004586-67.